NO169896B - 3 S-3-ALKYLBENZOKSAZINDERIVATER - Google Patents
3 S-3-ALKYLBENZOKSAZINDERIVATER Download PDFInfo
- Publication number
- NO169896B NO169896B NO883791A NO883791A NO169896B NO 169896 B NO169896 B NO 169896B NO 883791 A NO883791 A NO 883791A NO 883791 A NO883791 A NO 883791A NO 169896 B NO169896 B NO 169896B
- Authority
- NO
- Norway
- Prior art keywords
- compound
- methyl
- benzoxazine
- formula
- dihydro
- Prior art date
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 19
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical class FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 abstract description 12
- 150000005130 benzoxazines Chemical class 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 abstract description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229960001699 ofloxacin Drugs 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- -1 cyclic amino acid Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- CGPHGPCHVUSFFA-NSHDSACASA-N (2s)-1-(4-methylphenyl)sulfonylpyrrolidine-2-carboxylic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1[C@H](C(O)=O)CCC1 CGPHGPCHVUSFFA-NSHDSACASA-N 0.000 description 1
- JUSWZYFYLXTMLJ-JTQLQIEISA-N (2s)-1-(benzenesulfonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1S(=O)(=O)C1=CC=CC=C1 JUSWZYFYLXTMLJ-JTQLQIEISA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- XNIVKSPSCYJKBL-UHFFFAOYSA-N 2h-1,2-benzoxazine-6-carboxylic acid Chemical compound O1NC=CC2=CC(C(=O)O)=CC=C21 XNIVKSPSCYJKBL-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- BVHSAZFNVBBGNX-UHFFFAOYSA-N 7,8-difluoro-3-methyl-3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1=CC(F)=C(F)C2=C1NC(C)CO2 BVHSAZFNVBBGNX-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 description 1
- 229930182820 D-proline Natural products 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- DJIWKBNZEOPEAM-NUBCRITNSA-N piperidine-2-carboxylic acid;(2r)-piperidine-2-carboxylic acid Chemical compound OC(=O)C1CCCCN1.OC(=O)[C@H]1CCCCN1 DJIWKBNZEOPEAM-NUBCRITNSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Substituerte benzoksazinderivater med formel. hvori Xog X, hver står for et halogenatom og Rstår alkylgruppe med 1 til 4 karbonatomer. Forbindelsene kan fremstilles ved at 3S-3-alkyl-7,8-dihalo-gen-2, 3-dihydro-4H-/1 , iJJbenzoksazin med formelomsettes med dietyletoksymetylenmalonat med formel. De substituerte benzoksazinderivater er optisk aktive og egner seg for fremstilling av optisk aktive ofloksacin-derivater og analoger derav.Substituted benzoxazine derivatives of formula. wherein X and X, each represent a halogen atom and R is an alkyl group having 1 to 4 carbon atoms. The compounds can be prepared by formulating 3S-3-alkyl-7,8-dihalogen-2,3-dihydro-4H- [1,1] benzoxazine with formula with diethylethoxymethylene malonate of formula. The substituted benzoxazine derivatives are optically active and are suitable for the preparation of optically active ofloxacin derivatives and analogues thereof.
Description
Den foreliggende oppfinnelse vedrører 3-S-3-alkylbenzoksazin-derivater med formel The present invention relates to 3-S-3-alkylbenzoxazine derivatives with formula
og det særegne ved benzoksazinderivatene i henhold til oppfinnelsen er at X]_ og X2 hver står for et halogenatom og R^ står for en alkylgruppe med fra 1 til 4 karbonatomer. and the peculiarity of the benzoxazine derivatives according to the invention is that X]_ and X2 each stand for a halogen atom and R^ stands for an alkyl group with from 1 to 4 carbon atoms.
Disse trekk ved oppfinnelsen fremgår av patentkravet. These features of the invention appear in the patent claim.
De nevnte optisk aktive benzoksazinderivater er nyttige som utgangsmaterial for fremstilling av optisk aktive ofloksacin-derivater og analoger derav. The aforementioned optically active benzoxazine derivatives are useful as starting material for the production of optically active ofloxacin derivatives and analogues thereof.
Ofloksacin ((±)-9-fluor-3-metyl-10-(4-metyl-l-piperazinyl)-7-okso-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoksazin-6-karbok-sylsyre) er kjent å være et utmerket syntetisk antimikrobielt middel som omhandlet i publisert japansk patentsøknad (OPI) 46986/82. Bakgrunnen for den foreliggende oppfinnelse er at ofloksacin har et asymetrisk karbonatom i 3-stillingen og oppnås som et racemat (spesifikk dreining [a]D = 0°) ved hjelp av kjente prosesser. Ved hjelp av den foreliggende oppfinnelse kan man lett oppnå optisk aktive ofloksacinforbindelser og det ble i denne forbindelse funnet at 3S-metylforbindelsen har en antimikrobiell aktivitet som er omtrent to ganger høyere enn for (±)-forbindelsen og en akutt giftighet (LD^q) som er mindre enn for (±)-forbindelsen bestemt i mus ved intravenøs tilfør-sel. I den samme sammenheng ble det funnet at 3R-metylforbindelsen har en antimikrobiell aktivitet som bare er omtrent 1/10 til 1/100 ganger aktiviteten av (±)-forbindelsen, mens den har en akutt giftighet som omtrent tilsvarer (±)-forbindelsen. 3S-metylformen av ofloksacin er således funnet å ha meget ønskelige egenskaper, dvs. økt antimikrobiell aktivitet og nedsatt giftighet, og forventes å være et meget nyttig farmasøytisk middel sammenlignet med (±)-forbindelsen. Videre har 3S-metylforbindelsene av ofloksacin i fri- form markert høyere vannoppløselighet sammenlignet med (±)-forbindelsen og kan anvendes som injiserbare preparater. Ofloxacin ((±)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1 ,4]benzoxazine-6-carboxylic acid) is known to be an excellent synthetic antimicrobial agent as disclosed in Published Japanese Patent Application (OPI) 46986/82. The background for the present invention is that ofloxacin has an asymmetric carbon atom in the 3-position and is obtained as a racemate (specific rotation [a]D = 0°) using known processes. With the help of the present invention, one can easily obtain optically active ofloxacin compounds and it was found in this connection that the 3S-methyl compound has an antimicrobial activity that is approximately twice as high as that of the (±) compound and an acute toxicity (LD^q) which is smaller than for the (±) compound determined in mice by intravenous administration. In the same context, it was found that the 3R-methyl compound has an antimicrobial activity that is only about 1/10 to 1/100 times that of the (±) compound, while it has an acute toxicity that is about the same as the (±) compound. The 3S-methyl form of ofloxacin has thus been found to have very desirable properties, i.e. increased antimicrobial activity and reduced toxicity, and is expected to be a very useful pharmaceutical agent compared to the (±) compound. Furthermore, the 3S-methyl compounds of ofloxacin in free form have markedly higher water solubility compared to the (±) compound and can be used as injectable preparations.
Som et resultat av undersøkelser med det formål å komme frem til 3S-metylformen med høyere aktivitet, blant de to isomerer av ofloksacin, ble det funnet at forbindelser med den følgende formel (I) er nyttige som utgangsmaterial for syntese av slike 3S-alkylisomerer av ofloksacin. As a result of investigations aimed at finding the 3S-methyl form with higher activity, among the two isomers of ofloxacin, it was found that compounds of the following formula (I) are useful as starting materials for the synthesis of such 3S-alkyl isomers of ofloxacin.
Formålet for den foreliggende oppfinnelse er således et nytt utgangsmaterial representert ved den ovenfor beskrevne formel (I) nyttig for syntese av optisk aktive ofloksacinforbindelser. The purpose of the present invention is thus a new starting material represented by the above-described formula (I) useful for the synthesis of optically active ofloxacin compounds.
De nye utgangsmaterialer i samsvar med oppfinnelsen med formel (I) kan fremstilles i samsvar med reaksjonsskjemaet som illustrert i det følgende. The new starting materials in accordance with the invention with formula (I) can be prepared in accordance with the reaction scheme as illustrated in the following.
I det siste trinn oppvarmes (IB) med dietyletoksymetylenmalonat C2H5OCH=C(COOC2H5)2• I det ovenstående har n, X1( X2, Ri, R2 og R3 den ovennevnte betydning, og X3 er en karboksylgruppe eller et reaktivt derivat derav, f.eks. en aktiv ester, et halogenid eller et syreanhydrid av karboksylsyren. In the last step (IB) is heated with diethylethoxymethylene malonate C2H5OCH=C(COOC2H5)2• In the above, n, X1( X2, Ri, R2 and R3 have the above meaning, and X3 is a carboxyl group or a reactive derivative thereof, e.g. eg an active ester, a halide or an acid anhydride of the carboxylic acid.
I den ovennevnte prosess kondenseres 3-alkyl-7,8-dihalogen-2,3-dihydro-4H-[1,4]-benzoksazinet (II) med en cyklisk aminosyre eller et reaktivt derivat derav (III) ved amidbindingsdannelse for å danne forbindelsen (IV). Kondensasjonsreaksjonen kan gjennomføres enten ved hjelp av en aktiv estermetode, syrean-hydridmetoden eller DCC-metoden, men generelt blir forbindelse (II) og et syreklorid (III) hvori X3 er -C0C1 omsatt i et organisk løsningsmiddel som f.eks. halogenerte hydrokarboner, f.eks. diklormetan, i nærvær av en syreakseptor som f.eks. pyridin, trietylamin eller kaliumkarbonat, ved romtemperatur under omrøring. Reaksjonsproduktet kan isoleres og renses på konvensjonell måte, f.eks. ved krystallisasjon, kolonnekromatografering, etc. In the above process, the 3-alkyl-7,8-dihalo-2,3-dihydro-4H-[1,4]-benzoxazine (II) is condensed with a cyclic amino acid or a reactive derivative thereof (III) by amide bond formation to form the compound (IV). The condensation reaction can be carried out either by means of an active ester method, the acid hydride method or the DCC method, but generally compound (II) and an acid chloride (III) in which X3 is -COC1 are reacted in an organic solvent such as e.g. halogenated hydrocarbons, e.g. dichloromethane, in the presence of an acid acceptor such as e.g. pyridine, triethylamine or potassium carbonate, at room temperature with stirring. The reaction product can be isolated and purified in a conventional way, e.g. by crystallization, column chromatography, etc.
Ved denne kondensasjonsreaksjon, når den ene eller den annen av de.to isomerer av den cykliske aminosyre eller dets reaktive derivat (III), dvs. en S-forbindelse eller en R-forbindelse, anvendes, kan separering av diastereomerblandingen av forbindelsen (IV) gjennomføres på lett måte. Mer spesifikt blir derivater (III), som f.eks. S- eller R-prolin, S- eller R-pipekolsyre (piperidin-2-karboksylsyre), etc, passende anvendt. De mest foretrukne forbindelser (III) inkluderer (S)-N-benzensulfonylprolin og (S)-N-p-toluensulfonylprolin. In this condensation reaction, when one or the other of the two isomers of the cyclic amino acid or its reactive derivative (III), i.e. an S-compound or an R-compound, is used, separation of the diastereomer mixture of the compound (IV) is carried out in an easy way. More specifically, derivatives (III), such as e.g. S- or R-proline, S- or R-pipecolic acid (piperidine-2-carboxylic acid), etc, suitably used. The most preferred compounds (III) include (S)-N-benzenesulfonylproline and (S)-N-p-toluenesulfonylproline.
Den diastereomere blanding av forbindelse (IV) kan separeres The diastereomeric mixture of compound (IV) can be separated
ved hjelp av fraksjonert krystallisasjon, kromatografering under anvendelse av silikagel, etc, som en bærer, eller en kombinasjon derav, og 3S-alkyl-4-substituerte-[ 1,4]benzoksazinderivater (IA) oppnås. by means of fractional crystallization, chromatography using silica gel, etc., as a carrier, or a combination thereof, and 3S-alkyl-4-substituted-[1,4]benzoxazine derivatives (IA) are obtained.
Den således separerte diastereomer (IA) hydrolyseres, vanligvis under basiske forhold, til å danne et 3S-alkyl-7,8-dihalogen-2,3-dihydro-4H-[1,4]benzoksazin (IB). The thus separated diastereomer (IA) is hydrolyzed, usually under basic conditions, to form a 3S-alkyl-7,8-dihalo-2,3-dihydro-4H-[1,4]benzoxazine (IB).
Når forbindelsen med formel (IB) oppvarmes med dietyletoksymetylenmalonat ved foretrukket 130 til 140°C kan forbindelsen (IC) fremstilles. When the compound of formula (IB) is heated with diethylethoxymethylene malonate at preferably 130 to 140°C, the compound (IC) can be prepared.
Forbindelsen i samsvar med oppfinnelsen med formel (IC) kan omdannes til 3S-alkyl-pyridobenzoksazinforbindelser som 3S-9-fluor-2,3-dihydro-3-metyl-10-(4-metyl-l-piperazinyl)-7-okso-7H-pyrido[1,2,3-de][1,4]benzoksazin-6-karboksylsyre (ofloksacin) som beskrevet i europeisk patent EP 206283-A. The compound according to the invention with formula (IC) can be converted into 3S-alkyl-pyridobenzoxazine compounds such as 3S-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo -7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (ofloxacin) as described in European patent EP 206283-A.
Oppfinnelsen illustreres ved hjelp av de etterfølgende eksempler. The invention is illustrated by means of the following examples.
EKSEMPEL EXAMPLE
Fremstilling av dietyl[3S-7,8-difluor-3-metyl-2,3-dihydro-4H-[1,4]_benzoksazin-4-yl]metylenmalonat. Preparation of diethyl [3S-7,8-difluoro-3-methyl-2,3-dihydro-4H-[1,4]_benzoxazin-4-yl]methylene malonate.
Til 1,13 g 3S-7,8-difluor-2,3-dihydro-3-metyl-4H-[1,4]benzok-sazin tilsettes 1,58 g dietyletoksymetylenmalonat og blandingen omrøres ved 130 til 140°C i 70 min. Reaksjonsblandingen under-kastes som sådan kolonnekromatografering under anvendelse av 50 g silikagel og elueres med kloroform og gir 2,47 g dietyl-[3S-7,8-difluor-3-metyl-2, 3-dihydro-4H-[1,4]benzoksazin-4-yl]-metylenmalonat. To 1.13 g of 3S-7,8-difluoro-2,3-dihydro-3-methyl-4H-[1,4]benzoxazine, 1.58 g of diethylethoxymethylene malonate is added and the mixture is stirred at 130 to 140°C for 70 my. The reaction mixture is subjected as such to column chromatography using 50 g of silica gel and eluting with chloroform to give 2.47 g of diethyl-[3S-7,8-difluoro-3-methyl-2,3-dihydro-4H-[1,4 ]benzoxazin-4-yl]-methylene malonate.
[a]D = +250,4° (c = 4,275, CHC13) [a]D = +250.4° (c = 4.275, CHC13)
NMR (CDCI3) 6 (<pp>m): NMR (CDCl3) 6 (<pp>m):
1,22 - 1,42 (9H, m), 3,90 - 4,44 (7H, m), 6,74 - 6,88 1.22 - 1.42 (9H, m), 3.90 - 4.44 (7H, m), 6.74 - 6.88
(2H, m), 7,78 (1H, s). (2H, m), 7.78 (1H, s).
Det følgende er et eksempel på fremstilling av utgangsmaterial for fremstilling av forbindelser ifølge oppfinnelsen, nemlig henholdsvis 3S-7, 8-dif luor-2 , 3-dihydro-3-metyl-4- [ (S) -N-paratoluensulfonylpropyl] -4H-[1,4]benzoksazin (IA) og 33-7,8-difluor-2, 3-dihydro-3-metyl-lH-[1, 4]'benzoksazin (IB) . The following is an example of the preparation of starting material for the preparation of compounds according to the invention, namely 3S-7,8-difluoro-2,3-dihydro-3-methyl-4-[(S)-N-paratoluenesulfonylpropyl]-4H -[1,4]benzoxazine (IA) and 33-7,8-difluoro-2,3-dihydro-3-methyl-1H-[1,4]'benzoxazine (IB).
(IA) En oppløsning av et cyklisk aminosyreklorid, fremstilt fra 61,9 g (S)-N-ptoluensulfonylprolin og tionylklorid, i 350 ml tørt diklormetan ble sakte tilsatt dråpevis til en oppløsning av 22,8 g (±)-7,8-difluor-2,3-dihydro-3-metyl-4H-[1,4]benzoksazin og 28 ml pyridin i 300 ml tørt diklormetan ved romtemperatur under omrøring. Omrøringen ble fortsatt i ytterligere fire timer ved romtemperatur. Reaksjonsblandingen ble vasket i rekkefølge med 10 % (IA) A solution of a cyclic amino acid chloride, prepared from 61.9 g of (S)-N-ptoluenesulfonylproline and thionyl chloride, in 350 ml of dry dichloromethane was slowly added dropwise to a solution of 22.8 g of (±)-7.8 -difluoro-2,3-dihydro-3-methyl-4H-[1,4]benzoxazine and 28 ml of pyridine in 300 ml of dry dichloromethane at room temperature with stirring. Stirring was continued for a further four hours at room temperature. The reaction mixture was washed sequentially with 10%
saltsyre, en mettet vandig oppløsning av natriumhydrogen-karbonat og en mettet vandig oppløsning av natriumklorid og tørket over vannfritt magnesiumsulfat. Diklormetanet ble fjernet ved destillasjon og den oljeaktige rest bie oppløst i 200 ml etylacetat. Til oppløsningen ble sakte tilsatt dråpevis 750 ml n-heksan under omrøring hvorved krystaller av 3R-metylforbindelsen øyeblikkelig falt ut. De utfelte krystaller ble separert ved filtrering og filtratet ble konsentrert til tørrhet under redusert trykk. Resten ble underkastet kolonnekromatografering under anvendelse av 500 g silikagel og eluert med benzen/etylacetat (volumforhold 50/1 til 25/1) og ga et oljeaktig produkt. Det oljeaktige produkt ble oppløst i 500 ml etanol og oppløsningen fikk stå ved romtemperatur i ett døgn for utfelling av krystaller. Etanolen ble avdestillert og til de således isolerte krystaller ble det tilsatt dietyleter og n-heksan, etterfulgt av filtrering. Faststoffet ble tørket under redusert trykk og ga 33,4 g 3S-7,8-difluor-2,3-dihydro-3-metyl-4-[(S)-N-p-toluensul-fonylprolyl]-4H-[1, 4] benzoksazin ((IA) hvori X]_ = X2 = F, R]_ = CH3, R2 = p-toluensulf onyl, og n = 1) med et smeltepunkt 107-108°C. hydrochloric acid, a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate. The dichloromethane was removed by distillation and the oily residue was dissolved in 200 ml of ethyl acetate. To the solution was slowly added dropwise 750 ml of n-hexane with stirring, whereby crystals of the 3R-methyl compound immediately precipitated out. The precipitated crystals were separated by filtration and the filtrate was concentrated to dryness under reduced pressure. The residue was subjected to column chromatography using 500 g of silica gel and eluting with benzene/ethyl acetate (volume ratio 50/1 to 25/1) to give an oily product. The oily product was dissolved in 500 ml of ethanol and the solution was allowed to stand at room temperature for one day for precipitation of crystals. The ethanol was distilled off and diethyl ether and n-hexane were added to the crystals thus isolated, followed by filtration. The solid was dried under reduced pressure to give 33.4 g of 3S-7,8-difluoro-2,3-dihydro-3-methyl-4-[(S)-N-p-toluenesulfonylprolyl]-4H-[1,4 ] benzoxazine ((IA) in which X]_ = X2 = F, R]_ = CH3, R2 = p-toluenesulfonyl, and n = 1) with a melting point of 107-108°C.
[ct]D = +70,7° (c = 0,953, kloroform) [ct]D = +70.7° (c = 0.953, chloroform)
IR ^KBf (cm-1): 1685, 1510, 1490 IR ^KBf (cm-1): 1685, 1510, 1490
maks max
Elementæranalyse for C2i<H>22<F>2N2°4s: Elemental analysis for C2i<H>22<F>2N2°4s:
Teoretisk (%): C 57,79, H 5,08, N 6,42 Theoretical (%): C 57.79, H 5.08, N 6.42
Funnet (%): C 58,05, H 5,14, N 6,47 Found (%): C 58.05, H 5.14, N 6.47
(IB) 111 etanol ble oppløst 32,8 g av forbindelsen (IA) opp-nådd i det foregående, og 300 ml IN natriumhydroksyd ble tilsatt dertil, etterfulgt av koking under tilbakeløp i tre timer. Etanolen ble fjernet ved destillasjon og den oljeaktig rest bie ekstrahert med benzen. Ekstrakten ble vasket med en mettet vandig oppløsning av natriumklorid, (IB) 111 ethanol was dissolved 32.8 g of the compound (IA) obtained in the foregoing, and 300 ml of 1N sodium hydroxide was added thereto, followed by refluxing for three hours. The ethanol was removed by distillation and the oily residue was extracted with benzene. The extract was washed with a saturated aqueous solution of sodium chloride,
.tørket over natriumsulfat og destillert ved å fjerne benzen. Resten ble underkastet kolonnekromatografering under anvendelse av 200 g silikagel som en bærer og benzen som et elueringsmiddel og ga 12,7 g (utbytte 91,4 %) .dried over sodium sulfate and distilled to remove benzene. The residue was subjected to column chromatography using 200 g of silica gel as a carrier and benzene as an eluent to give 12.7 g (yield 91.4%)
3S-7,8-difluor-2,3-dihydro-3-metyl-4H-[1,4]benzoksazin som et oljeaktig produkt. 3S-7,8-difluoro-2,3-dihydro-3-methyl-4H-[1,4]benzoxazine as an oily product.
[a]D = -9,6° (c = 2,17, kloroform) [a]D = -9.6° (c = 2.17, chloroform)
Den absolutte konfigurasjon av denne forbindelse ble bestemt å være en S-konfigurasjon ved hjelp av røntgen-analyse av hydrokloridet. The absolute configuration of this compound was determined to be an S configuration by X-ray analysis of the hydrochloride.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO883791A NO169896C (en) | 1985-06-20 | 1988-08-25 | 3 S-3-ALKYLBENZOKSAZINDERIVATER |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13471285 | 1985-06-20 | ||
| JP60226499A JPH0720946B2 (en) | 1985-10-11 | 1985-10-11 | Optically active 3-methylbenzoxazine derivative and process for producing the same |
| JP1649686 | 1986-01-28 | ||
| NO862426A NO166131C (en) | 1985-06-20 | 1986-06-18 | ANALOGUE PROCEDURE FOR THE PREPARATION OF S (-) - PYRIDOBENZOKSAZINE COMPOUNDS. |
| NO883791A NO169896C (en) | 1985-06-20 | 1988-08-25 | 3 S-3-ALKYLBENZOKSAZINDERIVATER |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO883791L NO883791L (en) | 1986-12-22 |
| NO883791D0 NO883791D0 (en) | 1988-08-25 |
| NO169896B true NO169896B (en) | 1992-05-11 |
| NO169896C NO169896C (en) | 1992-08-19 |
Family
ID=27519821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO883791A NO169896C (en) | 1985-06-20 | 1988-08-25 | 3 S-3-ALKYLBENZOKSAZINDERIVATER |
Country Status (1)
| Country | Link |
|---|---|
| NO (1) | NO169896C (en) |
-
1988
- 1988-08-25 NO NO883791A patent/NO169896C/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO883791D0 (en) | 1988-08-25 |
| NO169896C (en) | 1992-08-19 |
| NO883791L (en) | 1986-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO166131B (en) | ANALOGUE PROCEDURE FOR THE PREPARATION OF S (-) - PYRIDOBENZOKSAZINE COMPOUNDS. | |
| AU778694B2 (en) | Process for the preparation of naproxene nitroxyalkylesters | |
| Wright et al. | An effective process for the isolation of docosahexaenoic acid in quantity from cod liver oil | |
| NO169896B (en) | 3 S-3-ALKYLBENZOKSAZINDERIVATER | |
| JPH0327534B2 (en) | ||
| FI62066B (en) | FRAMEWORK FOR ANTITROMBOTIC CYCLOHEXYL PHENYL DERIVATIVES | |
| AU2020442000B2 (en) | New crystalline form of vascular leakage blocker compound | |
| Playtis et al. | Pseudonucleoside analogs. Synthesis and spectral properties of 5-(cis-3-hydroxymethylcyclopentane) uracil, a carbocyclic analog of 2', 3'-dideoxypseudouridine | |
| US4211706A (en) | 9-Deoxy-9α,6-nitrilo or 6,9α-imino-17,18-didehydro-PGF compounds | |
| KR900004695B1 (en) | Piperidine compounds and pharmaceutical uses thereof | |
| JP3207017B2 (en) | Method for producing benzylsuccinic acid derivative and intermediate for producing the same | |
| Kashima et al. | Nucleophilic ring-opening reactions of morpholin-2-ones. A resolution of dl-(secondary-alkyl) amines | |
| WO1999012923A1 (en) | Stereoisomeric indole compounds, process for the preparation of the same, and use thereof | |
| US4238622A (en) | D,L-2-Amino-4-(2-aminoethoxy)-trans-but-3-enoic acid derivatives | |
| JP2004099494A (en) | Method for producing optically active tricyclic compound | |
| EP0240338B1 (en) | Butenoic acid derivatives | |
| US4170596A (en) | Novel monoesters of cis-cyclopentenediol, process for preparation thereof, and process for preparation of lactones from the monoesters | |
| KR100248370B1 (en) | Preparation of intermediate of (-)-3(s)-methylpyrido benzoxizine derivative | |
| NZ201938A (en) | Anthranilic acid esters,and pharmaceutical compositions containing such | |
| NO149922B (en) | FLUORED ALKENYLAMINES | |
| JP2724383B2 (en) | Method for producing (S) -benzoxazine derivative | |
| US4217284A (en) | Process for preparation of optically pure lactones from monoesters of cis-cyclopentenediol | |
| Sheehan et al. | Synthesis and reactions of 7-hydrazonocephalosporanates | |
| KR0141657B1 (en) | Optically active 1-phenylpyrrolidone derivatives | |
| SI8811867A8 (en) | Optically active derivative of benzoxazine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |